IRCCS Policlinico San Donato
- Address
- lock Available on a paid plan
Congenital, Hereditary, and Neonatal Diseases
At IRCCS Policlinico San Donato, research in congenital and hereditary disorders focuses on hereditary angioedema, with studies aimed at improving preventive care and understanding treatment performance in younger patients.
- Evaluating new options for the prophylactic management of hereditary angioedema
- Studying safety and how the body handles treatment in pediatric patients with C1-inhibitor hereditary angioedema
- Supporting better long-term control of a rare inherited condition
This area brings together rare-disease expertise with a strong focus on testing therapies that may help reduce attacks and improve day-to-day stability for affected children and families.
Digestive System Diseases
Clinical trials in digestive system diseases at this site center on ulcerative colitis, a chronic inflammatory bowel disease, with the goal of improving symptom control and intestinal healing.
- Assessing whether new therapies can improve endoscopic outcomes and symptomatic remission
- Comparing treatment effectiveness in moderately to severely active ulcerative colitis
- Advancing care for patients living with persistent intestinal inflammation
The research reflects a practical effort to find better ways to control disease activity, ease ongoing symptoms, and support more durable remission for people with this condition.
Nutritional and Metabolic Diseases
The nutritional and metabolic disease portfolio includes studies in obesity and overweight, exploring whether new treatments can improve health outcomes and reduce related medical risks.
- Testing therapies intended to support weight management and broader health improvement
- Evaluating whether treatment can lower morbidity and mortality in adults with obesity
- Addressing the long-term burden of excess body weight and related complications
This work highlights an important area of metabolic research, with a focus on helping patients achieve meaningful health benefits beyond weight reduction alone.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 81 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 77 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 29 by active trials.
- 1Novo Nordisk A/S5active
lock +28 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S8trials
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in IRCCS Policlinico San Donato
lock Showing 1 of 64 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | Amgen Inc. | Phase III | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 81 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Deucrictibant | 5 | Unknown | 2022-10-10 | 2026-04-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.